SEARCH

SEARCH BY CITATION

References

  • 1
    Page MI. The reactivity of β-lactams, the mechanism of catalysis and the inhibition of β-lactamases. Curr Pharm Des 1999; 5: 895913.
  • 2
    Bush K. β-Lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev 1988; 1: 109123.
  • 3
    Buynak JD. Understanding the longevity of the β-lactam antibiotics and of antibiotic/β-lactamase inhibitor combinations. Biochem Pharmacol 2006; 71: 930940.
  • 4
    Philippon A, Labia R, Jacoby G. Extended-spectrum β-lactamases. Antimicrob Agents Chemother 1989; 33: 11311136.
  • 5
    Cantón R, Coque TM. The CTX-M β-lactamase pandemic. Curr Opin Microbiol 2006; 9: 466475.
  • 6
    Knox JR. Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob Agents Chemother 1995; 39: 25932601.
  • 7
    Nicolas-Chanoine MH. Inhibitor-resistant β-lactamases. J Antimicrob Chemother 1997; 40: 13.
  • 8
    Bonomo RA, Rice LB. Inhibitor resistant class A β-lactamases. Front Biosci 1999; 4: e34e41.
  • 9
    Chaibi EB, Sirot D, Paul G, Labia R. Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 1999; 43: 447458.
  • 10
    Blázquez J, Baquero MR, Cantón R, Alós I, Baquero F. Characterization of a new TEM-type β-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Antimicrob Agents Chemother 1993; 37: 20592063.
  • 11
    Henquell C, Sirot D, Chanal C et al. Frequency of inhibitor-resistant TEM β-lactamases in Escherichia coli isolates from urinary tract infections in France. J Antimicrob Chemother 1994; 34: 707714.
  • 12
    Leflon-Guibout V, Ternat G, Heym B, Nicolas-Chanoine MH. Exposure to co-amoxiclav as a risk factor for co-amoxiclav-resistant Escherichia coli urinary tract infection. J Antimicrob Chemother 2002; 49: 367371.
  • 13
    Sanders CC, Iaconis JP, Bodey GP, Samonis G. Resistance to ticarcillin–potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 β-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother 1988; 32: 13651369.
  • 14
    Gheorghiu R, Yuan M, Hall LM, Livermore DM. Bases of variation in resistance to β-lactams in Klebsiella oxytoca isolates hyperproducing K1 beta-lactamase. J Antimicrob Chemother 1997; 40: 533541.
  • 15
    Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557584.
  • 16
    Fernández-Cuenca F, Pascual A, Martínez-Martínez L. Hyperproduction of AmpC β-lactamase in a clinical isolate of Escherichia coli associated with a 30 bp deletion in the attenuator region of ampC. J Antimicrob Chemother 2005; 56: 251252.
  • 17
    Goussard S, Sougakoff W, Mabilat C, Bauernfeind A, Courvalin P. An IS1-like element is responsible for high-level synthesis of extended-spectrum β-lactamase TEM-6 in Enterobacteriaceae. J Gen Microbiol 1991; 137: 26812687.
  • 18
    Wu PJ, Shannon K, Phillips I. Mechanisms of hyperproduction of TEM-1 β-lactamase by clinical isolates of Escherichia coli. J Antimicrob Chemother 1995; 36: 927939.
  • 19
    Stapleton P, Wu PJ, King A, Shannon K, French G, Phillips I. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother 1995; 39: 24782483.
  • 20
    Xiang X, Shannon K, French G. Mechanism and stability of hyperproduction of the extended-spectrum β-lactamase SHV-5 in Klebsiella pneumoniae. J Antimicrob Chemother 1997; 40: 525532.
  • 21
    Lartigue MF, Leflon-Guibout V, Poirel L, Nordmann P, Nicolas-Chanoine MH. Promoters P3, Pa/Pb, P4, and P5 upstream from blaTEM genes and their relationship to β-lactam resistance. Antimicrob Agents Chemother 2002; 46: 40354037.
  • 22
    Martinez JL, Cercenado E, Rodríguez-Creixems M, Vincente-Pérez MF, Delgado-Iribarren A, Baquero F. Resistance to β-lactam/clavulanate. Lancet 1987; 2: 1473.
  • 23
    Miro E, Del Cuerpo M, Navarro F, Sabate M, Mirelis B, Prats G. Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction. J Antimicrob Chemother 1998; 42: 535538.
  • 24
    Reguera JA, Baquero F, Pérez-Déaz JC, Martínez JL. Factors determining resistance to β-lactam combined with β-lactamase inhibitors in Escherichia coli. J Antimicrob Chemother 1991; 27: 569575.
  • 25
    Boyd DA, Tyler S, Christianson S et al. Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum β-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. Antimicrob Agents Chemother 2004; 48: 37583764.
  • 26
    Zhou XY, Bordon F, Sirot D, Kitzis MD, Gutmann L. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 β-lactamase conferring resistance to β-lactamase inhibitors. Antimicrob Agents Chemother 1994; 38: 10851089.
  • 27
    Naas T, Nordmann P. OXA-type β-lactamases. Curr Pharm Des 1999; 5: 865879.
  • 28
    Chaïbi EB, Farzaneh S, Morand A et al. Problems encountered in the characterization of IRT β-lactamase-producing clinical Escherichia coli isolates intermediate-resistant to cephalothin. J Antimicrob Chemother 1996; 37: 190191.
  • 29
    Thompson C, Amyes S. TRC-1: emergence of a clavulanic acid-resistant TEM β-lactamase in a clinical strain. FEMS Microbiol Lett 1992; 43: 113117.
  • 30
    Sirot D, Chanal C, Bonnet R, De Champs C, Bret L. Inhibitor resistant TEM-33 β-lactamase in a Shigella sonnei isolate. Antimicrob Agents Chemother 2001; 45: 21792180.
  • 31
    Vedel G, Belaaouaj A, Gilly L et al. Clinical isolates of Escherichia coli producing TRI β-lactamases: novel TEM-enzymes conferring resistance to β-lactamase inhibitors. J Antimicrob Chemother 1992; 30: 449462.
  • 32
    Wang X, Minasov G, Shoichet BK. The structural bases of antibiotic resistance in the clinically derived mutant β-lactamases TEM-30, TEM-32, and TEM-34. J Biol Chem 2002; 277: 3214932156.
  • 33
    Thomas VL, Golemi-Kotra D, Kim CH, Vakulenko SB, Mobashery S, Shoichet BK. Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM β-lactamase. Biochemistry 2005; 44: 93309338.
  • 34
    Henquell C, Chanal C, Sirot D, Labia R, Sirot J. Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM β-lactamases from clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1995; 39: 427430.
  • 35
    Canica MM, Lu CY, Krishnamoorthy R, Paul GC. Molecular diversity and evolution of blaTEM genes encoding β-lactamases resistant to clavulanic acid in clinical E. coli. J Mol Evol 1997; 44: 5765.
  • 36
    Payne DJ, Cramp R, Winstanley DJ, Knowles DJC. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important β-lactamases. Antimicrob Agents Chemother 1994; 38: 767772.
  • 37
    Bonomo RA, Rudin SA, Shlaes DM. Tazobactam is a potent inactivator of selected inhibitor-resistant class A β-lactamases. FEMS Microbiol Lett 1997; 148: 5962.
  • 38
    Kaye KS, Gold HS, Schwaber MJ et al. Variety of β-lactamases produced by amoxicillin–clavulanate-resistant Escherichia coli isolated in the Northeastern United States. Antimicrob Agents Chemother 2004; 48: 15201525.
  • 39
    Wong JS, Mohd Azri ZA, Subramaniam G, Ho SE, Palasubramaniam S, Navaratnam P. β-Lactam resistance phenotype determination in Escherichia coli isolates from University Malaya Medical Centre. Malays J Pathol 2003; 25: 113119.
  • 40
    Miró E, Navarro F, Mirelis B et al. Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant β-lactamases at a university hospital in Barcelona, Spain, over a 3-year period. Antimicrob Agents Chemother 2002; 46: 39913994.
  • 41
    Pérez-Moreno MO, Pérez-Moreno M, Carulla M, Rubio C, Jardí AM, Zaragoza J. Mechanisms of reduced susceptibility to amoxycillin–clavulanic acid in Escherichia coli strains from the health region of Tortosa (Catalonia, Spain). Clin Microbiol Infect 2004; 10: 234241.
  • 42
    Leflon-Guibout V, Speldooren V, Heym B, Nicolas-Chanoine MH. Epidemiological survey of amoxicillin–clavulanate resistance and corresponding molecular mechanisms in Escherichia coli isolates in France: new genetic features of blaTEM genes. Antimicrob Agents Chemother 2000; 44: 27092714.
  • 43
    Bradford PA, Bratu S, Urban C et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin Infect Dis 2004; 39: 5560.
  • 44
    Girlich D, Karim A, Poirel L, Cavin MH, Verny C, Nordmann P. Molecular epidemiology of an outbreak due to IRT-2 β-lactamase-producing strains of Klebsiella pneumoniae in a geriatric department. J Antimicrob Chemother 2000; 45: 467473.
  • 45
    Libert JM, Naudin F, Mougeot C, Sirot D. Détection en routine des β-lactamases TEM résistentes aux inhibiteurs (IRT) et des oxacillinases (OXA) chez Escherichia coli. Pathol Biol 1997; 45: 3440.
  • 46
    Oliver A, Pérez-Vázquez M, Martínez-Ferrer M, Baquero F, De Rafael L, Cantón R. Ampicillin–sulbactam and amoxicillin–clavulanate susceptibility testing of Escherichia coli isolates with different β-lactam resistance phenotypes. Antimicrob Agents Chemother 1999; 43: 862867.
  • 47
    Thomson CJ, Miles RS, Amyes SGB. Susceptibility testing with clavulanic acid: fixed concentration versus fixed ratio. Antimicrob Agents Chemother 1995; 39: 25912592.
  • 48
    Vanjak D, Mulleys C, Picard B, Bergogne-Bérézin X, Lambert-Zechovsky X. Activity of β-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to β-lactam agents. Eur J Clin Microbiol Infect Dis 1995; 14: 972978.
  • 49
    Hunter JE, Corkill JE, McLennan AG, Fletcher JN, Hart CA. Plasmid encoded β-lactamases resistant to inhibition by clavulanic acid produced by calf faecal coliforms. Res Vet Sci 1993; 55: 367370.
  • 50
    Arpin C, Labia R, Dubois V, Noury P, Souquet M, Quentin C. TEM-80, a novel inhibitor-resistant β-lactamase in a clinical isolate of Enterobacter cloacae. Antimicrob Agents Chemother 2002; 46: 11831189.
  • 51
    Lemozy J, Sirot D, Chanal C et al. First characterization of inhibitor-resistant TEM (IRT) β-lactamases in Klebsiella pneumoniae strains. Antimicrob Agents Chemother 1995; 39: 25802582.
  • 52
    Granier SA, Nguyen Van JC, Kitzis MD, Goldstein FW, Leflon-Guibout V, Nicolas-Chanoine MH. First description of a TEM-30 (IRT-2)-producing Klebsiella oxytoca isolate. Antimicrob Agents Chemother 2002; 46: 11581159.
  • 53
    Liebana E, Batchelor M, Hopkins KL et al. Longitudinal farm study of extended-spectrum β-lactamase-mediated resistance. J Clin Microbiol 2006; 44: 16301634.
  • 54
    Sirot D, Recule C, Chaibi EB et al. A complex mutant of TEM-1 β-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate. Antimicrob Agents Chemother 1997; 41: 13221325.
  • 55
    Fiett J, Palucha A, Miaczynska B et al. A novel complex mutant β-lactamase, TEM-68, identified in a Klebsiella pneumoniae isolate from an outbreak of extended-spectrum β-lactamase-producing klebsiellae. Antimicrob Agents Chemother 2000; 44: 14991505.
  • 56
    Neuwirth C, Madec S, Siebor E et al. TEM-89 β-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3. Antimicrob Agents Chemother 2001; 45: 35913594.
  • 57
    Poirel L, Mammeri H, Nordmann P. TEM-121, a novel complex mutant of TEM-type β-lactamase from Enterobacter aerogenes. Antimicrob Agents Chemother 2004; 48: 45284531.
  • 58
    Robin F, Delmas J, Chanal C, Sirot D, Sirot J, Bonnet R. TEM-109 (CMT-5), a natural complex mutant of TEM-1 β-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5). Antimicrob Agents Chemother 2005; 49: 44434447.
  • 59
    Robin F, Delmas J, Archambaud M, Schweitzer C, Chanal C, Bonnet R. CMT-type β-lactamase TEM-125, an emerging problem for extended-spectrum β-lactamase detection. Antimicrob Agents Chemother 2006; 50: 24032408.
  • 60
    Robin F, Delmas J, Schweitzer C et al. Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. Antimicrob Agents Chemother 2007; 51: 13041309.
  • 61
    Baquero F, Negri MC. Selective compartments for resistant microorganisms in antibiotic gradients. Bioessays 1997; 19: 731736.
  • 62
    Galán JC, Morosini MI, Baquero MR, Reig M, Baquero F. Haemophilus influenzae blaROB-1 mutations in hypermutagenic ΔampC Escherichia coli conferring resistance to cefotaxime and β-lactamase inhibitors and increased susceptibility to cefaclor. Antimicrob Agents Chemother 2003; 47: 25512557.
  • 63
    Randegger CC, Hachler H. Amino acid substitutions causing inhibitor resistance in TEM β-lactamases compromise the extended-spectrum phenotype in SHV extended-spectrum β-lactamases. J Antimicrob Chemother 2001; 47: 547554.
  • 64
    Stapleton PD, Shannon KP, French GL. Construction and characterization of mutants of the TEM-1 β-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to β-lactamase inhibitors. Antimicrob Agents Chemother 1999; 43: 18811887.
  • 65
    Dubois V, Poirel L, Arpin C et al. SHV-49, a novel inhibitor-resistant β-lactamase in a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 44664469.
  • 66
    Prinarakis EE, Miriagou V, Tzelepi E, Gazouli M, Tzouvelekis LS. Emergence of an inhibitor-resistant β-lactamase (SHV-10) derived from an SHV-5 variant. Antimicrob Agents Chemother 1997; 41: 838840.
  • 67
    Machado E, Coque TM, Cantón R et al. Dissemination in Portugal of CTX-M-15-, OXA-1-, and TEM-1-producing Enterobacteriaceae strains containing the aac(6′)-Ib-cr gene, which encodes an aminoglycoside- and fluoroquinolone-modifying enzyme. Antimicrob Agents Chemother 2006; 50: 32203221.